Checklist for standardized reporting of drug-drug interaction management guidelines

Checklist for standardized reporting of drug-drug interaction management guidelines

Diğer sürümleri göster (1)

Purpose: Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare provi...

Detaylı Bibliyografya
Asıl Yazarlar:	Floor-Schreudering, A, Geerts, A, Aronson, J, Bouvy, M, Ferner, R, De Smet, P
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2014

Benzer Materyaller

Checklist for standardized reporting of drug-drug interaction management guidelines.
Yazar:: Floor-Schreudering, A, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Towards improved drug-drug interaction management guidelines
Yazar:: Floor-Schreudering, A, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Pharmacogenetics and adverse drug reactions
Yazar:: Ferner, R, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Clarification of terminology in drug safety.
Yazar:: Aronson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Communicating information about drug safety.
Yazar:: Ferner, R, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.
Yazar:: Aronson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

National differences in publishing papers on adverse drug reactions.
Yazar:: Ferner, R, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

EIDOS: a mechanistic classification of adverse drug effects.
Yazar:: Ferner, R, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Monitoring for the Adverse Effects of Drugs
Yazar:: Coleman, J, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Joining the DoTS: new approach to classifying adverse drug reactions.
Yazar:: Aronson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Preventability of drug-related harms - part I: a systematic review.
Yazar:: Ferner, R, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Defining rewardable innovation in drug therapy.
Yazar:: Aronson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

The toxicological significance of post-mortem drug concentrations in bile
Yazar:: Ferner, RE, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Nominal ISOMERs (Incorrect spellings of medicines eluding researchers)-variants in the spellings of drug names in PubMed: a database review
Yazar:: Ferner, R, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.
Yazar:: McDowell, SE, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity
Yazar:: Ferner, RE, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Serious drug interactions.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (1993)

Classifying drug interactions.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (2004)

Beneficial drug interactions.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (1994)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (2008)

Designing and Psychometry of the Evaluation Checklist for the Registration and Labeling Guidelines of Anesthetic Drugs in the Operating Room
Yazar:: Parisa Moradimajd, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Reporting guidelines for human microbiome research: the STORMS checklist
Yazar:: Mirzayi, C, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Communicating information about drug interactions
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (2007)

Interactions that matter: 10 Antiarrhythmic drugs
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (1987)

Reporting guideline checklists are not quality evaluation forms: they are guidance for writing
Yazar:: Logullo, P, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions /
Yazar:: Aronson, Jeffrey K.
Baskı/Yayın Bilgisi: (2006)

Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (2005)

The reporting checklist for public versions of guidelines: RIGHT-PVG
Yazar:: Xiaoqin Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Checking and correction of drug information in the standards of care and clinical guidelines
Yazar:: B. K. Romanov
Baskı/Yayın Bilgisi: (2018-02-01)

RMJ research series – Using a Reporting Guideline (Checklist)
Yazar:: D. Hopkinson, ve diğerleri
Baskı/Yayın Bilgisi: (2020-03-01)

Clinical pharmacology. Adverse drug interactions.
Yazar:: Aronson, J, ve diğerleri
Baskı/Yayın Bilgisi: (1981)

Reporting Guidelines for Healthcare Guideline Adaptations: An Interpretation of the RIGHT-Ad@pt Checklist
Yazar:: GONG Liyun, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Drug interactions-information, education, and the British National Formulary.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (2004)

Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.
Yazar:: Hauben, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Yazar:: Jinghong Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM
Yazar:: Xuanlin Li, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Reporting guideline checklists are not quality evaluation forms: they are guidance for writing
Yazar:: Patricia Logullo, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

Guidelines of research biosimilar drugs
Yazar:: R. . Ivanov, ve diğerleri
Baskı/Yayın Bilgisi: (2014-04-01)

Adverse drug reactions: definitions, diagnosis, and management.
Yazar:: Edwards, I, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
Yazar:: Laura Molenaar-Kuijsten, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)